三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
发生FGFR的突变的肿瘤比例
发生FGFR的突变的肿瘤比例
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:181KB
图片尺寸:1830*756
同报告图片
/
4
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
所属报告:
信达生物-投资价值分析报告:快速崛起的国际化Biopharma-210708(60页).pdf
打包全文图表
相关数据
anti-FGFR2b单抗与SOS1抑制剂国内临床进展
fCDoja/lk4EgICAgICAgICB8IOeglOWPkeS8geS4miAgIHwg6YCC5bqU55eHICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCDpnbbngrkgICAgICAgICB8IOS4tOW6iui/m+WxlSAgICAgICAgICAgfAp8LS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS18Cnwg6LSd546b5aal54+g5Y2V5oqXIHwg5YaN6byO5Yy76I2vICAgfCBGR0ZSMmIg6L+H6KGo6L6+55qE5pma5pyf6IOD55mM5oiW6IOD6aOf566h57uT5ZCI6YOo77yIRy9HRUrvvInnmYwgfCBGR0ZSMmIgICAgICAgfCBJSUkg5pyfICAgICAgICAgICAgIHwKfCBUUUIyMjEwICAgICAgfCDmraPlpKflpKnmmbQgICB8IOaZmuacn+aBtuaAp+iCv+eYpCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgRkdGUjJiICAgICAgIHwgSSDmnJ8gICAgICAgICAgICAgICB8CnwgSFdTMTE2ICAgICAgIHwg5Lq656aP5Yy76I2vICAgfCDmmZrmnJ/lrp7kvZPnmKQgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgRkdGUjJiICAgICAgIHwg6I635om55Li05bqK77yIMjAyNS4077yJIHwKfCBIWVAtNjU4OSAgICAgfCDmsYflrofliLboja8gICB8IOaZmuacn+WunuS9k+eYpOOAgei9rOenu+aAp+mdnuWwj+e7huiDnuiCuueZjCAgICAgICAgICAgICAgICAgfCBTT1MxICAgICAgICAgfCBJL0lJIOacnyAgICAgICAgICAgIHwKfCBaRzIwMDEgICAgICAgfCDms73nkp/liLboja8gICB8IOaZmuacn+WunuS9k+eYpCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCBLUkFTL1NPUzEgICAgfCBJL0lJIOacnyAgICAgICAgICAgIHwKfCBCSS0xNzAxOTYzICAgfCDli4PmnpfmoLzmrrfmoLznv7AgfCDmmZrmnJ/lrp7kvZPnmKTjgIHohbrnmYzjgIHovaznp7vmgKfpnZ7lsI/nu4bog57ogrrnmYzjgIHovaznp7vmgKfnu5PogqDnm7TogqDnmYwgfCBLUkFTIEcxMkMgICAgfCBJIOacnyAgICAgICAgICAgICAgIHwKfCBIVy0wNzEwMjEgICAgfCDkurrnpo/ljLvoja8gICB8IOaZmuacn+WunuS9k+eYpCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCBTT1MxICAgICAgICAgfCBJIOacnyAgICAgICAgICAgICAgIHwKfCBTWUgtMjAzOCAgICAgfCDnn7Poja/pm4blm6IgICB8IOaZmuacn+WunuS9k+eYpCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCBLUkFTL1NPUzEgICAgfCBJIOacnyAgICAgICAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muaRqeeGteWMu+iNr+OAgeaLm+WVhuivgeWIuA==
收藏
行业数据
2025-12-31
原图定位
查看详情
FGFR2基因的三种不同突变类型:融合,点突
PHxiZWdpbl9vZl9ib3h8PnwgRkdGUjLnqoHlj5gv5pS55Y+Y57G75Z6LICAgICAgIHwg576O5Zu95bm05Y+R55eF5Lq65pWwICAgICAgICAgfAp8LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfAp8IEZ1c2lvbu+8iOiejeWQiO+8iSAgICAgICAgICAgfCB+NC41SyAtIDE0SyAgICAgICAgICAgIHwKfCBNdXRhdGlvbu+8iOeCueeqgeWPmO+8iSAgICAgICB8IH42LjVLIC0gMjFLICAgICAgICAgICAgfAp8IFRvdGFsIEZHRlIyIGFsdGVyYXRpb25zICB8IH4xMSAtIDM1SyBwYXRpZW50cyAgICAgfAoK6LWE5paZ5p2l5rqQ77ya6Ieq54S26IK/55ik5a2m57u86L+w5p2C5b+XMjAxNzx8ZW5kX29mX2JveHw+
收藏
行业数据
2025-10-10
原图定位
查看详情
美国FGFR2基因突变在不同实体瘤的发病人数
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
收藏
行业数据
2025-10-10
原图定位
查看详情
全球首个FGFR4抑制剂联合IO在HCC的临床设计:依帕戈替尼联合阿替利珠单抗的临床二期试验方案
PHxiZWdpbl9vZl9ib3h8PnwgUGFydCB8IERvc2UgUmVnaW1lbiAgICAgICB8IFNhbXBsZSBTaXplIChOKSB8CnwtLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS18CnwgQSAgICB8IDE4MG1nIFFEICAgICAgICAgICB8IDYgICAgICAgICAgICAgICB8CnwgQSAgICB8IDMyMG1nIFFEICAgICAgICAgICB8IDYgICAgICAgICAgICAgICB8CnwgQSAgICB8IDE2MG1nIEJJRCAgICAgICAgICB8IDggICAgICAgICAgICAgICB8CnwgQSAgICB8IDIyMG1nIEJJRCAgICAgICAgICB8IDMzICAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrlhazlj7hQUFQ8fGVuZF9vZl9ib3h8Pg==
收藏
行业数据
2025-10-10
原图定位
查看详情
全球几款早于和誉依帕戈替尼进入临床阶段的FGFR4抑制剂,大部分都已经停止开发
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
收藏
行业数据
2025-10-10
原图定位
查看详情
和誉FGFR2/3抑制剂将针对胃癌和软骨发育不全症两个适应症展开
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
收藏
行业数据
2025-10-10
原图定位
查看详情
全球主要已经上市获批的FGFR抑制剂销售及未来销售预测
PHxiZWdpbl9vZl9ib3h8Pnwg5bm05Lu9ICAgfCBKJkogLSBFcmRhZml0aW5pYiAo55m+5LiH576O5YWDKSB8IEluY3l0ZS9Jbm5vdmVudCAtIFBlbWlnYXRpbmliICjnmb7kuIfnvo7lhYMpIHwgQnJpZGdlQmlvIC0gSW5maWdyYXRpbmliICjnmb7kuIfnvo7lhYMpIHwgVGFpaG8vT3RzdWthIC0gRnV0aWJhdGluaWIgKOeZvuS4h+e+juWFgykgfAp8LS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18CnwgMjAyMSAgIHwgODAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IDUwICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAwICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAwICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDIyICAgfCAxMjAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgODAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IDAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IDAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfAp8IDIwMjMgICB8IDE4MCAgICAgICAgICAgICAgICAgICAgICAgICAgfCAxMDAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyNCAgIHwgMjIwICAgICAgICAgICAgICAgICAgICAgICAgICB8IDEyMCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAwICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAwICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDI1RSAgfCAyODAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMTUwICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IDUwICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IDAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfAp8IDIwMjZFICB8IDM1MCAgICAgICAgICAgICAgICAgICAgICAgICAgfCAxNzAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgNzAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMzAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyN0UgIHwgNDMwICAgICAgICAgICAgICAgICAgICAgICAgICB8IDE5MCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCA5MCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCA0MCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDI4RSAgfCA1MjAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMjEwICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IDExMCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IDUwICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfAp8IDIwMjlFICB8IDYyMCAgICAgICAgICAgICAgICAgICAgICAgICAgfCAyMzAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMTMwICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgNjAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAzMEUgIHwgNzIwICAgICAgICAgICAgICAgICAgICAgICAgICB8IDI1MCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAxNTAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCA3MCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDMxRSAgfCA4MjAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMjcwICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IDE3MCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IDgwICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfAp8IDIwMzJFICB8IDkwMCAgICAgICAgICAgICAgICAgICAgICAgICAgfCAyOTAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMTkwICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgOTAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrmi5vllYbor4HliLjvvIjpppnmuK/vvInvvIxFdmFsdWF0ZSBQaGFybWHpooTmtYvvvIgyMDI15bm0OeaciO+8iTx8ZW5kX29mX2JveHw+
收藏
行业数据
2025-10-10
原图定位
查看详情
全球约30%的肝细胞癌患者存在异常的FGF19-FGFR4通路改变,依帕戈替尼(ABSK011)的独特设计MoA
fCDlnLDljLogICB8IOavj+W5tOaWsOWinueXheS+i+aVsCB8CnwtLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tfAp8IOWFqOeQgyAgIHwg57qmMzDkuIcgICAgICAgICB8Cnwg5Lit5Zu9ICAgfCDnuqYxNeS4hyAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuFBQVO+8jOS+neW4leaIiOabv+WwvOmAmui/h+mdtuWQkUZHRjE5IC0gRkdGUjQg6YCa6Lev5rK755aX6IKd55mM
收藏
行业数据
2025-10-10
原图定位
查看详情
FGFR家族的主要四类亚型,在人体不同类型癌症中的突变类型(基因扩增/点突变/基因融合重排)
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
收藏
行业数据
2025-10-10
原图定位
查看详情
全球在研的FGFR2b单抗产品
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
收藏
行业数据
2025-09-24
原图定位
查看详情
用于胃癌治疗的FGFR靶点药物竞争格局
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
收藏
竞争格局
2025-09-19
原图定位
查看详情
全球在研FGFR2bADC
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
收藏
行业数据
2025-07-07
原图定位
查看详情
图表30FGFR4与FGFR1-3结构差异
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
收藏
行业数据
2025-04-11
原图定位
查看详情
FGFR信号通路以及抑制剂
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
收藏
行业数据
2024-12-09
原图定位
查看详情
全球已上市选择性FGFR小分子抑制剂
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
收藏
行业数据
2024-12-09
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
中国是世界上胆管癌发病率最高的国家之一,我国消化道肿瘤约占全部癌症发病率的43.3%,胆管癌在消化道肿瘤中占比约 3%,属于罕见病的一种,据此我们测算,我国每年胆管癌发病人数约 6 万人。目前晚期胆管癌已有的系统治疗疗效较差,标准治疗(顺铂联合吉西他滨)总生存期小于 1 年。成纤维细胞生长因子受体(FGFR)在肿瘤细胞增殖、存活、迁移和血管生成中发挥着重要作用,其中在胆管癌患者中突变比例占 25%。胆管癌最常见的遗传事件之一是 FGFR2 基因融合/重排,靶向 FGFR 对存在此类突变的胆管癌具有明显的治疗作用。
行业数据
原图定位
当前图表所属:
信达生物-投资价值分析报告:快速崛起的国际化Biopharma-210708(60页).pdf
国内PD-1单抗在霍奇金淋巴瘤适应症上的研发进展
中国市场已获批PD-1/PD-L1单抗产品
经2019年或2020年医保谈判被纳入医保目录的PD-1产品治疗费用情况
2020年国产PD-1单抗销售额及单价对比
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》